Ignite Creation Date:
2024-05-05 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00202059
Status:
COMPLETED
Last Update Posted:
2015-12-16
First Post:
2005-09-13
Brief Title:
Effects of Zometa and Physical Activity on Bone Density in Women Receiving Chemotherapy for Breast Cancer
Sponsor:
HealthPartners Institute
Organization:
HealthPartners Institute
Study Overview
Official Title:
The Effects of Zoledronic Acid Zometa and Physical Activity on Bone Density in Women Receiving Chemotherapy for Breast Cancer
Status:
COMPLETED
Status Verified Date:
2007-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the effect of zoledronic acid and physical activity on preventing bone loss in women aged 40 - 55 who are receiving chemotherapy for breast cancer The primary objective is to compare the percent change in the lumbar spine bone mineral density BMD from baseline to 12 months for women who are randomized to either Group A intravenous zoledronic acid oral calcium carbonate and vitamin D or Group B a prescribed physical activity program oral calcium carbonate and vitamin D
Detailed Description:
Background Breast cancer diagnosis accounts for 32 of all new cancer cases in US women with approximately 211300 women diagnosed in 2003 The majority of these women receive adjuvant chemotherapy which may lead to chemotherapy-induced menopause CIM in premenopausal women CIM often leads to accelerated bone loss osteopenia and eventual osteoporosis
Purpose The purpose of this study is to evaluate the effect of zoledronic acid and physical activity on preventing bone loss in women aged 40 - 55 who are receiving chemotherapy for breast cancer The primary objective is to compare the percent change in the lumbar spine bone mineral density BMD from baseline to 12 months for women who are randomized to either Group A intravenous zoledronic acid oral calcium carbonate and vitamin D or Group B a prescribed physical activity program oral calcium carbonate and vitamin D Secondary objectives are to compare the percent change between the groups in total hip BMD the incidence of vertebral fractures fatigue functional status and other cancer-related symptoms between the two groups
Methods Seventy-two women will be enrolled and randomized to one of two treatment groups For participants randomized to Group A intravenous zoledronic acid will be given every 3 months for the 12 month study period along with 2 tablets of calcium carbonate 600 mgvitamin D 200 IU daily For participants randomized to Group B a physical activity intervention designed to improve BMD will be prescribed and administered through the occupational rehabilitation department Group B participants will also take 2 tablets of calcium carbonate 600 mgvitamin D 200 IU daily BMD measurements at the lumbar spine and hip and an AP and lateral X-ray will be done at baseline and at 12 months after enrollment in the study using dual energy X-ray absorptiometry DXA Serum bone-specific alkaline phosphotase and N-telopeptide urine tests will be conducted at baseline and 12 months to evaluate bone resorption activity Other measures that will be assessed via questionnaires include fatigue Schwartz Cancer Fatigue Scale functional status SF-36 a 4-day food record and other cancer-related symptoms MD Anderson Symptom Inventory
Analysis Results will be analyzed on an intent-to-treat basis Descriptive statistics will be used to analyze demographic data tumor information dietary information and baseline BMD Differences between baseline means will be analyzed by t-tests The percent change in BMD between the two groups will be analyzed by analysis of covariance ANCOVA Differences in other measures will be analyzed by t-tests
Results Results of this study will be used to determine if zoledronic acid or physical activity affect BMD in young women who are receiving chemotherapy for breast cancer
Purpose The purpose of this study is to evaluate the effect of zoledronic acid and physical activity on preventing bone loss in women aged 40 - 55 who are receiving chemotherapy for breast cancer The primary objective is to compare the percent change in the lumbar spine bone mineral density BMD from baseline to 12 months for women who are randomized to either Group A intravenous zoledronic acid oral calcium carbonate and vitamin D or Group B a prescribed physical activity program oral calcium carbonate and vitamin D Secondary objectives are to compare the percent change between the groups in total hip BMD the incidence of vertebral fractures fatigue functional status and other cancer-related symptoms between the two groups
Methods Seventy-two women will be enrolled and randomized to one of two treatment groups For participants randomized to Group A intravenous zoledronic acid will be given every 3 months for the 12 month study period along with 2 tablets of calcium carbonate 600 mgvitamin D 200 IU daily For participants randomized to Group B a physical activity intervention designed to improve BMD will be prescribed and administered through the occupational rehabilitation department Group B participants will also take 2 tablets of calcium carbonate 600 mgvitamin D 200 IU daily BMD measurements at the lumbar spine and hip and an AP and lateral X-ray will be done at baseline and at 12 months after enrollment in the study using dual energy X-ray absorptiometry DXA Serum bone-specific alkaline phosphotase and N-telopeptide urine tests will be conducted at baseline and 12 months to evaluate bone resorption activity Other measures that will be assessed via questionnaires include fatigue Schwartz Cancer Fatigue Scale functional status SF-36 a 4-day food record and other cancer-related symptoms MD Anderson Symptom Inventory
Analysis Results will be analyzed on an intent-to-treat basis Descriptive statistics will be used to analyze demographic data tumor information dietary information and baseline BMD Differences between baseline means will be analyzed by t-tests The percent change in BMD between the two groups will be analyzed by analysis of covariance ANCOVA Differences in other measures will be analyzed by t-tests
Results Results of this study will be used to determine if zoledronic acid or physical activity affect BMD in young women who are receiving chemotherapy for breast cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CZOL446E | None | None | None |